Investors

Financials & Filings

Filing date Form Description Filing Group View
DEFA14A

Additional proxy soliciting materials - definitive

Proxy Filings
10-K

Annual report which provides a comprehensive overview of the company for the past year

Annual Filings
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
8-K

Report of unscheduled material events or corporate event

Current Reports
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
DEFA14A

Additional proxy soliciting materials - definitive

Proxy Filings
PREM14A

A preliminary proxy statement relating to a merger or acquisition

Mergers & Acquisitions
DEFA14A

Additional proxy soliciting materials - definitive

Proxy Filings
8-K

Report of unscheduled material events or corporate event

Current Reports
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
8-K

Report of unscheduled material events or corporate event

Current Reports
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
DEFA14A

Additional proxy soliciting materials - definitive

Proxy Filings
SC 13G/A

An amendment to the SC 13G filing

Other

Data provided by Kaleidoscope.

GNI Group, Ltd. (2160:Tokyo) (“GNI Japan”) holds an indirect, controlling interest in Gyre Therapeutics, Inc. From time to time, GNI Japan will disclose historical and forward looking information, which will include information about our business. We may not have previously disclosed such information. Please refer to https://www.gnipharma.com/ir/yuho/ for GNI Japan’s Investor Information and Securities Reports.